DRY CHEMISTRY IN PRECISION MEDICINE (Q2044561)
Jump to navigation
Jump to search
Project Q2044561 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DRY CHEMISTRY IN PRECISION MEDICINE |
Project Q2044561 in Italy |
Statements
56,600.0 Euro
0 references
113,200.0 Euro
0 references
50.0 percent
0 references
2 August 2016
0 references
28 June 2018
0 references
24 August 2018
0 references
DIATECH PHARMACOGENETICS S.R.L. A SOCIO UNICO
0 references
Q286403 (Deleted Item)
0 references
43°31'19.13"N, 13°14'39.77"E
0 references
INTRODUZIONE DIATECH PHARMACOGENETICS, NATA NEL 2010, OGGI CON UNA QUOTA DI MERCATO IN ITALIA DEL 70% Ê LEADER ASSOLUTA NEL SETTORE DELLA FARMACOGENETICA E DELLA PERSONALIZZAZIONE DELLE CURE. PRIORITARIO AMBITO DI APPLICAZIONE DELLE RICERCHE SVILUPPATE DA DIATECH PHARMACOGENETICS Ê QUELLO ANTITUMORALE. L`AZIENDA SOSTIENE LA PROPRIA RICERCA GRAZIE ALLA VENDITA E ALLO SVILUPPO DI TEST FARMACOGENETICI IMPIEGATI NELLA MEDICINA PERSONALIZZATA E GENETICA PARTENDO, PER PRIORITà , DALLE CURE PIù INVASIVE: QUELLE ANTITUMORALI. GRAZIE AI KIT FARMACOGENETICI SVILUPPATI DA DIATECH PHARMACOGENETICS Ê POSSIBILE, INFATTI, PERSONALIZZARE I TRATTAMENTI CHEMIOTERAPICI E RADIOTERAPICI, RENDENDOLI PIù EFFICACI E RIDUCENDONE GLI EFFETTI COLLATERALI. LE SOLUZIONI DI DIATECH PHARMACOGENETICS INTERESSANO, OLTRE IL COLON, ANCHE I TUMORI DEI POLMONI E DELLA PELLE; I TUMORI CEREBRALI; L`AMBITO CARDIOVASCOLARE. OGGI I TEST FARMACOGENETICI SI STANNO IMPONENDO COME OBBLIGATORI NELL¿USO DEI FARMACI ANTITUMO (Italian)
0 references
INTRODUCTION OF PHARECH PHARMACOGENETICS, BORN IN 2010, NOW WITH A MARKET SHARE IN ITALY OF 70 %, IT IS AN ABSOLUTE LEADER IN THE FIELD OF PHARMACOGENETICS AND PERSONALISATION OF TREATMENT. PRIORITY AREA OF APPLICATION OF THE RESEARCH DEVELOPED BY DIPECH PHARMACOGENETICS ÃO CANCER IS A MAJOR PRIORITY. THE COMPANY SUPPORTS ITS OWN RESEARCH THROUGH THE SALE AND DEVELOPMENT OF PHARMACOGENETIC TESTS USED IN PERSONALISED AND GENETIC MEDICINE BASED ON, FOR PRIMARITARED, THE TREATMENTS THAT ARE INVASIVE. ANTI-CANCER. AS A RESULT OF THE PHARMACOGENETIC KITS DEVELOPED BY DIOTECH PHARMACOGENETICS, IT IS POSSIBLE TO PERSONALISE CHEMOTHERAPY AND RADIOTHERAPEUTIC TREATMENTS, MAKING THEM EFFECTIVE AND REDUCING THEIR SIDE EFFECTS. PHARMACOGENETICS SOLUTIONS ALSO AFFECT LUNG AND SKIN CANCERS BEYOND THE COLON; BRAIN TUMOURS; CARDIOVASCULAR FIELD. NOWADAYS, THE PHARMACOGENETIC TESTS ARE BEING IMPOSED AS A MANDATORY REQUIREMENT FOR THE USE OF ANTIMUM DRUGS. (English)
0 references
INTRODUCTION DIATECH PHARMACOGÉNÉTIQUE, NÉE EN 2010, AVEC AUJOURD’HUI UNE PART DE MARCHÉ DE 70 % EN ITALIE DANS LE DOMAINE DE LA PHARMACOGÉNÉTIQUE ET DE LA PERSONNALISATION DES TRAITEMENTS. DOMAINE PRIORITAIRE D’APPLICATION DE LA RECHERCHE DÉVELOPPÉE PAR DIATECH PHARMACOGÉNÉTIQUE ÀŠ L’ANTICANCÉRE. L’ENTREPRISE SOUTIENT SES RECHERCHES GRÂCE À LA VENTE ET AU DÉVELOPPEMENT DE TESTS PHARMACOGÉNÉTIQUES UTILISÉS EN MÉDECINE PERSONNALISÉE ET GÉNÉTIQUE, À PARTIR, EN PRIORITÉ, DES TRAITEMENTS LES PLUS ENVAHISSANTS: LES ANTICANCÉREUX. GRÂCE AUX KITS PHARMACOGÉNÉTIQUES DÉVELOPPÉS PAR DIATECH PHARMACOGÉNÉTIQUE, IL EST POSSIBLE, EN FAIT, DE PERSONNALISER LES TRAITEMENTS DE CHIMIOTHÉRAPIE ET DE RADIOTHÉRAPIE, EN LES RENDANT PLUS EFFICACES ET EN RÉDUISANT LEURS EFFETS SECONDAIRES. LES SOLUTIONS DE DIATECH PHARMACOGÉNÉTIQUE AFFECTENT, OUTRE LE CÔLON, ÉGALEMENT LES TUMEURS DES POUMONS ET DE LA PEAU; TUMEURS CÉRÉBRALES; LE CHAMP CARDIOVASCULAIRE. LES TESTS PHARMACOGÉNÉTIQUES DEVIENNENT MAINTENANT OBLIGATOIRES DANS L’UTILISATION DE MÉDICAMENTS ANTICANCÉREUX (French)
16 December 2021
0 references
Identifiers
B43G17000080007
0 references